Genentech Announces Interim Results from Phase III HAVEN 2 Study

April 17, 2017

On April 16, 2017 Genentech announced interim results from the Phase III HAVEN 2 study evaluating emicizumab prophylaxis in children less than 12 years of age with hemophilia A and inhibitors to factor VIII. According to this Genentech’s press releases, “interim analysis after a median of 12 weeks of treatment, emicizumab prophylaxis showed a clinically meaningful reduction in the […]

Sign up for E-mails, Dateline Newsletter, and other ways to stay connected.